CUSIP 53566P109 · who reports it, how much, and how much it matters to them
9 of the 720 hedge fund managers we track reported shares of Lineage Cell Therapeutics, Inc. (NYSE: LCTX) on Form 13F for 30 June 2026. Between them they reported USD 74m. The largest position belongs to Broadwood Capital, at USD 65m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Broadwood Capital1 fund on PPLI.com | USD 65m | 3.4% |
| 2 | Millennium Management6 funds on PPLI.com | USD 4m | 0.0% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 1.8m | 0.0% |
| 4 | Marshall Wace LLP84 funds on PPLI.com | USD 1.7m | 0.0% |
| 5 | Squarepoint Ops7 funds on PPLI.com | USD 583,000 | 0.0% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 558,000 | 0.0% |
| 7 | Two Sigma Investments35 funds on PPLI.com | USD 71,981 | 0.0% |
| 8 | Voleon Capital Management13 funds on PPLI.com | USD 60,886 | 0.0% |
| 9 | Boothbay Fund Management2 funds on PPLI.com | USD 13,100 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Broadwood Capital | USD 65m | 3.4% |
| 2 | Renaissance Technologies | USD 1.8m | 0.0% |
| 3 | Millennium Management | USD 4m | 0.0% |
| 4 | Marshall Wace LLP | USD 1.7m | 0.0% |
| 5 | Squarepoint Ops | USD 583,000 | 0.0% |
| 6 | Voleon Capital Management | USD 60,886 | 0.0% |
| 7 | Citadel Advisors | USD 558,000 | 0.0% |
| 8 | Two Sigma Investments | USD 71,981 | 0.0% |
| 9 | Boothbay Fund Management | USD 13,100 | 0.0% |
Lineage Cell Therapeutics, Inc. trades under the symbol LCTX on the New York Stock Exchange. Its CUSIP, the code used on Form 13F, is 53566P109.
9 of the 720 hedge fund managers PPLI.com tracks reported Lineage Cell Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Broadwood Capital (USD 65m), Millennium Management (USD 4m), Renaissance Technologies (USD 1.8m), Marshall Wace LLP (USD 1.7m) and Squarepoint Ops (USD 583,000).
9 managers in our coverage reported it, and between them they run 193 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Broadwood Capital, where the position was 3.4% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Lineage Cell Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.